Trial Profile
Comparison between 5 - azacytidine treatment and 5 - azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Allogeneic stem cell therapy; Amsacrine; Busulfan; Cytarabine; Fludarabine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms VidazaAllo
- 20 Jul 2021 Results (n=162) assessing efficacy and safety compared HSCT following 5-aza pretreatment with continuous 5-aza treatment in patients with higher-risk MDS age 55-70 years, published in the Journal of Clinical Oncology..
- 21 Aug 2019 This trial has been completed in Germany according to European Clinical Trials Database record
- 04 Dec 2018 Primary endpoint (overall survival) has been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology